Examiner: SHI, GENBIN

Tech Center 1600 • Art Units: 1600 1628

This examiner grants 0% of resolved cases

Performance Statistics

—

Allow Rate

-60.0% vs TC avg

Total Applications

—

Interview Lift

Avg Prosecution Days

Based on 0 resolved cases, 2023–2026

3.1%

§101 Eligibility

9.3%

§102 Novelty

48.5%

§103 Obviousness

20.6%

§112 Clarity

App #	Title	Status	Assignee
18843599	USE OF IPTACOPAN FOR THE TREATMENT OF LUPUS NEPHRITIS	Non-Final OA	Novartis AG

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.